PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism
Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact underlying mechanism and therapeutic potential are largely unknown. Here we report that protein arginine methyltransferase 6 (PRMT6) is highly expressed in lung cancer and is required for cell metabolism, tumo...
Main Authors: | Mingming Sun, Leilei Li, Yujia Niu, Yingzhi Wang, Qi Yan, Fei Xie, Yaya Qiao, Jiaqi Song, Huanran Sun, Zhen Li, Sizhen Lai, Hongkai Chang, Han Zhang, Jiyan Wang, Chenxin Yang, Huifang Zhao, Junzhen Tan, Yanping Li, Shuangping Liu, Bin Lu, Min Liu, Guangyao Kong, Yujun Zhao, Chunze Zhang, Shu-Hai Lin, Cheng Luo, Shuai Zhang, Changliang Shan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522002416 |
Similar Items
-
PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1
by: Fei Xie, et al.
Published: (2023-04-01) -
PRMT1 is an important factor for medulloblastoma cell proliferation and survival
by: Xiao Gu, et al.
Published: (2022-12-01) -
A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth
by: Joanna L Gillis, et al.
Published: (2021-08-01) -
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue
by: Lakshmi Prabhu, et al.
Published: (2023-01-01) -
Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma
by: Jia Wang, et al.
Published: (2023-12-01)